Ting-Kuo Yao

Dr. Ting-Kuo Yao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TYTing-Kuo Yao
Ting-Kuo Yao
RLRu-Ping Lee
Ru-Ping Lee
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
TYTzai-Chiu Yu
Tzai-Chiu Yu
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Gouty arthritis, a prevalent inflammatory condition characterized by the deposition of monosodium urate crystals within joints, often results in debilitating pain and inflammation. Conventional therapeutic approaches, including nonsteroidal anti-inflammatory drugs, corticosteroids, and urate-lowering agents such as allopurinol and febuxostat, often have limitations such as adverse effects, drug interactions, and suboptimal patient compliance. This review presents a comprehensive overview of both established and emerging therapeutic strategies, developed between 2019 and 2024, for gouty arthritis; the review focuses on their mechanisms of action, efficacy, and safety profiles. Novel therapeutic approaches include pharmaceutical plant additives (e.g., Citrullus colocynthis, Atractylodes lancea), anti-inflammatory agents such as canakinumab and ozone therapy, and complementary therapies such as warm ginger compresses, Qingpeng ointment, and various lifestyle modifications. These strategies offer promising alternatives to conventional treatments by targeting uric acid metabolism, inflammatory pathways, and crystal formation, potentially reducing reliance on standard medications and minimizing adverse effects. Although therapies such as canakinumab have demonstrated significant efficacy in reducing gout flares, others such as polyphenol-rich foods offer favorable safety profiles. Further research, including large-scale clinical trials, is warranted to validate these findings and integrate these strategies into clinical practice to improve patient outcomes and quality of life.

18 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SCShi-Hsun Chiu
Shi-Hsun Chiu
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
TYTing-Kuo Yao
Ting-Kuo Yao
CPCheng-Huan Peng
Cheng-Huan Peng
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Background/Objectives: Osteoporosis and cardiovascular disease (CVD) share common risk factors and pathophysiological mechanisms, raising concerns about the cardiovascular implications of sclerostin inhibition. Romosozumab, a monoclonal antibody that targets sclerostin, is effective in increasing bone mineral density (BMD) and reducing fracture risk. However, evidence suggests that sclerostin inhibition may adversely affect vascular calcification, potentially increasing the risk of myocardial infarction (MI) and stroke. Methods: This review synthesizes data from clinical trials, such as ARCH, BRIDGE, and FRAME, alongside genetic studies and observational analyses, to evaluate the cardiovascular safety of romosozumab. PubMed was searched for relevant studies published within the last five years. Studies addressing the relationship between romosozumab and cardiovascular outcomes were included, emphasizing both its efficacy in osteoporosis management and potential cardiovascular risks. Results: Romosozumab significantly improves BMD and reduces fracture risk in postmenopausal women and men with osteoporosis. However, clinical trials report an increased incidence of major adverse cardiovascular events (MACE), particularly in patients with pre-existing cardiovascular conditions such as chronic kidney disease (CKD), diabetes, or prior CVD. Genetic studies indicate that SOST gene variants may also influence cardiovascular outcomes. Conclusions: While romosozumab is an effective treatment for osteoporosis, careful cardiovascular risk assessment is crucial before initiating therapy, especially for high-risk populations. Long-term studies are needed to evaluate chronic safety. Future therapeutic strategies should aim to maintain bone health while minimizing cardiovascular risks, ensuring a balance between efficacy and safety in osteoporosis treatment.

17 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YHYi-Ting Hung
Yi-Ting Hung
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
RLRu-Ping Lee
Ru-Ping Lee
TYTing-Kuo Yao
Ting-Kuo Yao
KYKuang-Ting Yeh
Kuang-Ting Yeh
Background: Denosumab, a receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor, demonstrates therapeutic effects beyond traditional osteoporosis management through the RANK/RANKL/osteoprotegerin pathway. Methods: This narrative review analyzed 37 studies (2018–2024) examining denosumab’s broader physiological effects and clinical applications. Results: Long-term safety data spanning 10 years showed sustained fracture prevention efficacy with a favorable benefit/risk profile. Compared to bisphosphonates, denosumab demonstrated superior outcomes in bone mineral density improvement and fracture risk reduction, particularly in elderly and frail populations. It enhanced muscular function by improving appendicular lean mass and grip strength while reducing fall risk. The drug showed potential cardiovascular benefits through its effects on cardiac and smooth muscle function. Notably, denosumab use was associated with reduced Type II diabetes mellitus risk through improved glucose metabolism. Additionally, it demonstrated promise in osteoarthritis treatment by suppressing osteoclast activity and chondrocyte apoptosis. While there are multisystem benefits, vigilance is required regarding adverse events, including hypocalcemia, infection risk, cutaneous reactions, and osteonecrosis of the jaw. Conclusions: Denosumab exhibits potential benefits in bone and systemic metabolism. Further research is needed to fully understand its therapeutic potential beyond osteoporosis and optimize clinical applications across different populations.

29 September 2025 in Life
Verified
Journal Article
Open access
PDF file
JCJer-Yung Chen
Jer-Yung Chen
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
RLRu-Ping Lee
Ru-Ping Lee
TYTing-Kuo Yao
Ting-Kuo Yao
CPCheng-Huan Peng
Cheng-Huan Peng
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Post-traumatic osteoarthritis (PTOA) is a distinct form of knee osteoarthritis characterized by accelerated joint degeneration following injury. It poses unique challenges in post-menopausal women due to hormonal changes and altered bone metabolism that create complex pathophysiological environments. This retrospective cohort study compared the effectiveness of different anti-osteoporotic medications in preventing total knee replacement (TKR) in 6155 postmenopausal women with PTOA treated between 2011 and 2021. We compared raloxifene and denosumab, with alendronate serving as the reference group. The primary outcome was TKR occurrence. Cox proportional hazards regression and inverse probability of treatment weighting (IPTW) were performed to estimate hazard ratios, with Kaplan–Meier survival analysis for time-to-event assessment. Participants’ mean (SD) age was 69.4 (10.0) years. Given the retrospective nature and typical delayed presentation of PTOA symptoms, cohort entry was defined as the concurrent diagnosis of PTOA and osteoporosis requiring anti-resorptive therapy. Over a mean follow-up of 5.47 years, 26 patients (0.42%) underwent TKR. Raloxifene was associated with a significantly reduced TKR risk compared to alendronate (IPTW-HR 0.81, 95% CI 0.67–0.99, p = 0.040), representing a 19% relative risk reduction. Kaplan–Meier analysis demonstrated raloxifene maintained the lowest cumulative TKR incidence compared to alendronate and denosumab over time, particularly beyond 5 years. These findings suggest that raloxifene may offer superior joint protection compared with alendronate and denosumab in postmenopausal women with PTOA, supporting its potential as a disease-modifying therapeutic option for this vulnerable population.

28 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JCJer-Yung Chen
Jer-Yung Chen
STShih-Hung Tsai
Shih-Hung Tsai
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
CPCheng-Huan Peng
Cheng-Huan Peng
TYTing-Kuo Yao
Ting-Kuo Yao
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Background: Romosozumab and teriparatide are approved osteoanabolic therapies for osteoporosis, but direct real-world comparisons remain limited. In this study, we evaluated comparative effectiveness and selected safety outcomes. Methods: Female patients with osteoporosis aged ≥ 50 years who initiated romosozumab or teriparatide were identified in the TriNetX Global Network from January 2020 through December 2025. Outcomes included any osteoporotic fracture, spine or hip fracture, major adverse cardiovascular events (MACE; a nonfatal composite of acute myocardial infarction and stroke), and all-cause mortality, which was analyzed separately. Propensity score matching balanced measured baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Results: After 1:1 propensity score matching, each matched cohort included 8616 patients, with follow-up administratively limited to 3 years. Romosozumab initiation was associated with lower risks of any osteoporotic fracture (445 vs. 832 events; HR, 0.68; 95% CI, 0.61–0.77) and spine or hip fracture (341 vs. 682 events; HR, 0.63; 95% CI, 0.55–0.72). The primary analysis also showed a lower estimated risk of MACE (145 vs. 255 events; HR, 0.80; 95% CI, 0.65–0.98), but this association was not consistent across sensitivity analyses. All-cause mortality did not differ significantly (81 vs. 126 events; HR, 0.96; 95% CI, 0.72–1.27). Conclusions: Romosozumab initiation was associated with lower fracture incidence than teriparatide initiation. The cardiovascular and mortality findings do not establish superiority, equivalence, or cardioprotection and should be interpreted cautiously.

13 April 2025 in Life
Verified
Journal Article
Open access
PDF file
WWWei-Hung Wang
Wei-Hung Wang
YHYi-Ting Hung
Yi-Ting Hung
CLChi Luo
Chi Luo
Wen-Tien WuWen-Tien Wu
Wen-Tien Wu
RLRu-Ping Lee
Ru-Ping Lee
Kuang-Ting YehKuang-Ting Yeh
Kuang-Ting Yeh
Hip fractures significantly affect mortality and quality of life in the elderly population. Although alpha-blockers are commonly prescribed for lower urinary tract symptoms after transurethral resection of the prostate (TURP), their long-term safety regarding fracture risk remains controversial. This study aimed to investigate whether long-term alpha-blocker use after TURP affects the risk of hip fractures requiring surgery in elderly men. This study included 6853 male patients aged ≥50 years who underwent TURP between 2000 and 2018. The alpha-blocker group (n = 1371) included patients who continued alpha-blocker treatment after TURP, while the control group (n = 5482) included those who had discontinued the medication. The primary outcome was hip fracture requiring surgical intervention. During follow-up (3.80 ± 1.64 years), hip fracture occurred in 4.2% of the alpha-blocker group versus 5.6% of controls. After adjusting for baseline characteristics and competing risk analysis, alpha-blocker use was associated with a significantly lower risk of hip fracture (p = 0.005). Subgroup analysis revealed particularly strong protective effects in patients with diabetes. Long-term use of alpha-blockers after TURP was associated with reduced hip fracture risk, particularly in patients with diabetes. These findings suggest the safety of continued alpha-blocker therapy after TURP in these patients.